Localization of trapping of 6-[18F]fluoro-L-m-tyrosine, an aromatic L- amino acid decarboxylase tracer for PET

Synapse

Volumn 34, Issue 2, 1999, Pages 111-123

  Brown, W Douglas ^a   DeJesus, Onofre T ^a   Pyzalski, Robert W ^a   Malischke, Lisamarie ^a   Roberts, Andrew D ^a   Shelton, Steven E ^a   Uno, Hideo ^a   Houser, W Dan ^a   Nickles, R Jerome ^a   Holden, James E ^a  

^a E3/311 CSC ^*

Author keywords

6 FMT; Dopamine; FluoroDOPA; Monoamine neurotransmitter; Positron emission tomography

Indexed keywords

AMINO ACID DECARBOXYLASE; CATECHOLAMINE; DOPAMINE; FLUORINE 18; FLUORODOPA F 18; META TYROSINE; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG DISTRIBUTION; ENZYME ACTIVITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHESUS MONKEY;

ANIMALS; BRAIN; DIHYDROXYPHENYLALANINE; FLUORINE RADIOISOTOPES; MACACA MULATTA; ORGAN SPECIFICITY; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TYROSINE;

EID: 0032887819     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199911)34:2<111::AID-SYN4>3.0.CO;2-0     Document Type: Article

References (66)

1. Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I. 1994. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res 667:295-299.
2. Barrio JR, Huang SC, Yu DC, Melega WP, Quintana J, Cherry SR, Jacobson A, Namavari M, Satyamurthy N, Phelps ME. 1996. Radiofluorinated L-m-tyrosines: new in-vivo probes for central dopamine biochemistry. J Cereb Blood Flow Metab 16:667-678.
3. Bogdanski D, Weissbach H, Udenfriend S. 1957. The distribution of serotonin 5-hydroxytryptophan decarboxylase, and monoamine oxidase in brain. J Neurochem 1:272-278.
4. 18F]-6-fluoroDOPA during positron emission tomography: elimination and metabolism in carbidopa treated subjects. Life Sci 39:2243-2252.
5. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, Marsden CD, Frackowiak RS. 1990. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 113:1539-1552.
6. Brown RM, Goldman PS. 1977. Catecholamines in neocortex of rhesus monkeys: regional distribution and ontogenetic development. Brain Res 124:576-580.
7. Brown RM, Crane AM, Goldman PS. 1979. Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates. Brain Res 168:133-150.
8. 18F]-L-6-fluoroDOPA and its metabolites in blood plasma is essential for accurate positron emission tomography studies. Life Sci 50:309-318.
9. Côté L Fahn, S. 1968. Some aspects of the biochemistry of the substantia nigra of the rhesus monkey. In: Barbeau A, Brunette JR, editors. Proceedings of the 2nd International Congress of Neurogenetics and Neuro-ophthalmology. Amsterdam: Excerpta Medica. p 311-317.
10. 18F]-fluoro-L-DOPA in the rat. Biochem Pharmacol 50:943-946.
11. Dedek J, Baumes R, Tien-Duc N, Gomeni R, Korf J. 1979. Turnover of free and conjugated (sulphonyloxy) dihydroxyphenylacetic acid and homovanillic acid in rat striatum. J Neurochem 33:687-695.
12. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. 1994. Performance characteristics of a whole-body PET scanner. J Nucl Med 35:1398-1406.
13. DeJesus OT, Mukherjee J. 1988. Radiobrominated m-tyrosine analog as potential CNS L-DOPA PET tracer. Biochem Biophys Res Commun 150:1027-1031.
14. DeJesus OT, Sunderland JJ, Chen C-A, Nickles RJ, Mukherjee J, Appelman EH. 1989. Synthesis of radiofluorinated m-tyrosine analogs as potential L-DOPA PET tracers. J Nucl Med 30:930.
15. DeJesus OT, Sunderland JJ, Nickles RJ, Mukherjee J, Appelman EH. 1990. Synthesis of radiofluorinated analogs of m-tyrosine as potential L-DOPA tracers via direct reaction with acetylhypofluorite. Int J Radiat Appl Inst Part A, Appl Radiat Isot 41:433-437.
16. 18F]fluoro-b-fluoromethylene-m-tyrosine. Brain Res 597:151-154.
17. DeJesus OT, Murali D, Nickles RJ. 1995. Synthesis of brominated and fluorinated ortho-tyrosine analogs as potential DOPA decarboxylase tracers. J Label Comp Radiopharm 37:147.
18. DeJesus OT, Endres CJ, Shelton SE, Nickles RJ, Holden JE. 1997. Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: comparison with 6-fluoroDOPA. J Nucl Med 38:630-636.
19. Deleu D, Sarre S, Ebinger G, Michotte Y. 1991. In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. Amicrodialysis study. Naunyn Schmiedebergs Arch Pharmacol 344:514-519.
20. Dhawan V, Ishikawa T, Patlak C, Chaly T, Robeson W, Belakhlef A, Margouleff C, Mandel F, Eidelberg D. 1996. Combined FDOPA and 3OMFD PET studies in Parkinson's disease. J Nucl Med 37:209-216.
21. 19F NMR. Biochem Biophys Res Commun 110:740-745.
22. 18F]fluoro-L-DOPA in the rhesus monkey brain. J Cereb Blood Flow Metab 11:726-734.
23. Doudet DJ, McLellan CA, Aigner TG, Wyatt RJ, Cohen RM. 1992. Delayed L-phenylalanine infusion allows for simultaneous kinetic analysis and improved evaluation of specific-to-nonspecific fluorine-18-DOPA uptake in brain. J Nucl Med 33:1383-1389.
24. Doudet DJ, Chan GLY, Holden JE, Morrison KS, Wyatt RJ, Ruth TJ. 1997. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology 36: 363-371.
25. Eidelberg D. 1992. Positron emission tomography studies in parkinsonism. Neurol Clinics 10:421-433.
26. Endres C, Swaminathan S, Ruoho A, Sievert M, DeJesus OT, Murali D, Holden J. 1995. Uptake mechanisms of PET DOPA analogs: amine affinities for monoamine granular and plasma membrane translocators. J Cereb Blood Flow Metab 15:8653.
27. Endres CJ, Swaminathan S, DeJesus OT, Sievert M, Ruoho AE, Murali D, Rommelfanger SG, Holden JE. 1997. Affinities of dopamine analogs for monoamine granular and plasma membrane transporters: implications for PET dopamine studies. Life Sci 60:2399-2406.
28. Fell V, Greenway AM, Hoskins JA. 1979. The metabolism of L-m-tyrosine in man. Biochem Med 22:246-255.
29. 18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem 48:1077-1082.
30. 18F]fluoro-L-dopa in human blood. J Nucl Med 29:363-369.
31. Firnau G, Chirakal R, Nahmias C, Garnett ES. 1991. Do the metabolites of 6-[F-18]fluoro-L-DOPA and of [F-18]fluoro-meta-L-tyrosine contribute to the F-18 accumulation in the human brain? J Label Comp Radiopharm 30:293-294.
32. Garnett S, Firnau G, Nahmias C, Chirakal R. 1983. Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res 280:169-171.
33. Guldberg HC, Marsden CA. 1975. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 27:135-206.
34. Hagen P. 1962. Observations on the substrate specificity of dopa decarboxylase from ox adrenal medulla, human phaeochromocytoma, and human argentaffinoma. Br J Pharmacol 18:175-182.
35. Hammerstad JP, Pate BD, Hewitt KA, Chan GL-Y, Ruth TJ, Calne DB. 1993. The transport of L-6-fluorodopa and its metabolites from blood to cerebrospinal fluid and brain. Ann Neurol 34:603-608.
36. Hardebo JE, Falck B, Owman C, Rosengren E. 1979. Studies on the enzymatic blood-brain barrier: quantitative measurements of DOPA decarboxylase in the wall of microvessels as related to the parenchyma in various CNS regions. Acta Physiol Scand 105:453-460.
37. 18F]fluoro-L-dopa kinetics in positron emission tomography. J Nucl Med 33:1472-1477.
38. Holden J, Vingerhoets F, Snow B, Chan GL-Y, Legg B, Morrison S, Adam M, Jivan S, Sossi V, Buckley KR, Ruth TJ. 1996. Links between 6-fluorodopa and 6-fluoro-3-O-methyldopa kinetics. In: Myers R, Cunningham V, Bailey D, Jones T, editors. Quantification of brain function using PET. San Diego: Academic Press. p 227-231.
39. Ichise M, Ballinger JR. 1997. Physiologic modeling of PET data: quantitative conflict and challenge. J Nucl Med 38:1266-1267.
40. Ishikawa T, Dhawan V, Patlak C et al. 1996. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase. In: Myers R, Cunningham V, Bailey D, Jones T, editors. Quantification of Brain Function Using PET. San Diego: Academic Press. p 232-236.
41. Jaeger C, Ruggiero D, Albert V, Job T, Reis D. 1984. Immunocytochemical localization of aromatic-L-amino acid decarboxylase. In: Björklund A, Hökfelt T, editors. Handbook of chemical neuroanatomy vol. 2, classical transmitters in the CNS, part I, vol. 2. Amsterdam: Elsevier. p 387-408.
42. 18F]fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates. Brain Res 750:264-276.
43. 18F]fluoro-L-m-tyrosine metabolism. Neurochem Res 23:513-517.
44. Juorio AV, Li X-M Walz, W Paterson IA. 1993. Decarboxylation of L-dopa by cultured mouse astrocytes. Brain Res 626:306-309.
45. Kirchgessner AL, Gershon MD, Liu KP, Tamir H. 1988. Costorage of serotonin binding protein with serotonin in the rat CNS. J Neurosci 8:3879-3890.
46. Kuntzman R, Shore P, Bogdanski D, Brodie BB. 1961. Microanalytical procedures for fluprometric assay of brain DOPA-5HTP decarboxylase, norepinephrine and serotonin, and a detailed mapping of decarboxylase activity in brain. J Neurochem 6:226-232.
47. 18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20:258-262.
48. Lloyd KG, Hornykiewicz O. 1972. Occurrence and distribution of aromatic L-amino acid (L-DOPA) decarboxylase in the human brain. J Neurochem 19:1549-1959.
49. Melamed E, Hefti F, Wurtman RJ. 1980. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 8:558-563.
50. 18F]fluoro-L-m-tyrosine: an L-3,4-dihydroxyphenylalanine analog for probing presynaptic dopaminergic function with positron emission tomography. J Neurochem 53:311-314.
51. 3H]L-dopa in rats. Biochem Pharmacol 39:1853-1860.
52. 18F]fluoro-β-fluoromethylene-m-tyrosine analogs, potential PET agents for presynaptic dopamine terminals: synthesis and spectroscopic characterization. Int J Radiat Appl Instr Part A, Appl Radiat Isot 43:969-977.
53. 18F]6-fluoro-L-m-tyrosine in the human brain. Mov Disord 10:298-304.
54. 18F]Fluoro-L-dopa. Int J Radiat Appl Instr Part A Appl Radiat Isot 43:989-996.
55. Patlak CS, Blasberg RG. 1985. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 5:584-590.
56. 18F]fluoro-L-dopa. Eur J Pharmacol 257:53-58.
57. Pscheidt G, Himwich HE. 1963. Reserpine, monoamine oxidase inhibitors, and distribution of biogenic amines in monkey brain. Biochem Pharmacol 12:65-71.
58. Rahman MK, Nagatsu T, Kato T. 1981. Aromatic L-amino acid decarboxylase activity in central and peripheral tissues and serum of rats with L-DOPA and L-5-hydroxytryptophan as substrates. Biochem Pharmacol 30:645-649.
59. Segal M, Deneau GA, Seevers MH. 1972. Levels and distribution of central nervous system amines in normal and morphine-dependent monkeys. Neuropharmacology 11:211-222.
60. Srinivasan K, Awapara J. 1978. Substrate specificity and other properties of DOPA decarboxylase from guinea pig kidneys. Biochim Biophys Acta 526:597-604.
61. Stout DB, Huang S-C, Melega WP, Raleigh MJ, Phelps ME, Barrio JR. 1998. Effects of large neutral amino acid concentrations on 6-[F-18]-Fluoro-L-DOPA kinetics. J Cereb Blood Flow Metab 18:43-51.
62. Tamir H. 1983. Serotonin-binding protein: function in synaptic vesicles. Trans NY Acad Sci 41:237-242.
63. 18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography. Acta Neurol Scand 81:24-30.
64. Tong JH, Smyth RG, D'Iorio A. 1979. Metabolism of m-tyrosine in the rat. Biochem Pharmacol 28:1029-1036.
65. Wahl L, Nahmias C. 1996. Modeling of fluorine-18-6-fluoro-L-Dopa in humans. J Nucl Med 37:432-437.
66. 18F]6-fluoro-3-O-methyl-L-dopa in the human brain. J Cereb Blood Flow Metab 14:664-670.